There’s a special energy in Mississippi this time of year. Students are back in class buzzing with school spirit, looking forward to an evening spent under Friday night lights. But amid all that energy, we’re sometimes hit with heartbreaking headlines: a young athlete collapsing on the football field, often with no warning. Too often, the cause is a condition that isn’t well known, and it’s one I’d like to shed some light on: Hypertrophic cardiomyopathy, or HCM.
HCM is a genetic condition in which part of the heart muscle becomes abnormally thickened. When severe, it can progress to obstructive HCM, meaning the thickened muscle blocks or slows the flow of blood out of the heart. This makes it harder for the heart to pump effectively and can trigger symptoms such as chest pain, shortness of breath, fainting, or fatigue. In the most serious cases, obstructive HCM can progress to heart failure or even sudden cardiac death.
Diagnosing HCM is not always easy, since its symptoms can be mistaken for less serious conditions. That makes awareness and early detection critical. The good news is that screening is not especially complicated, and here in Mississippi, we have cardiologists with the expertise to both diagnose and treat the condition.
For many years, treatment focused mainly on managing symptoms with medications, or in the most extreme cases, open-heart surgery or even a heart transplant. These options, while sometimes necessary, are invasive, costly, and carry significant risks.
Now, however, a new kind of therapy has emerged: cardiac myosin inhibitors. These medications directly target the underlying problem in obstructive HCM by helping the overactive heart muscle relax and pump more efficiently. In clinical studies, nearly 80 percent of patients on a myosin inhibitor experienced enough relief in their blood flow to move into the safe range, allowing many to avoid or delay surgery.
The first of these medications to be FDA-approved is mavacamten. It represents a breakthrough for patients with obstructive HCM, offering a therapy that goes beyond simply easing symptoms to actually address the cause of the disease.
Here in Mississippi, heart disease remains one of our most persistent and deadly health challenges. Too many lives are cut short, and too many families lose loved ones far earlier than they should. A proven, targeted treatment like mavacamten has the potential to help some Mississippians live longer, healthier lives. While only a small number of patients in our state may need this therapy, for those individuals it could mean the difference between living independently and facing open-heart surgery or a transplant.
Mississippians deserve the same access to innovative, life-changing care that patients in other states already have. We should not be last when it comes to heart health. As a physician, my hope is that every Mississippian diagnosed with obstructive HCM can benefit from the latest proven treatments when they need them. Our patients deserve nothing less.
Dr. Hays is a cardiologist at the Jackson Heart Clinic.
